Advanced glycation end products induce in vitro cross-linking of α-synuclein and accelerate the process of intracellular inclusion body formation

Journal of Neuroscience Research

Volumn 86, Issue 9, 2008, Pages 2071-2082

  Shaikh, Shamim ^a   Nicholson, Louise F B ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

synuclein; AGEs; Lewy bodies; Parkinson's disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA SYNUCLEIN; RECOMBINANT PROTEIN; ROTENONE;

ARTICLE; CELL CULTURE; CELL INCLUSION; CELL LYSATE; CONTROLLED STUDY; CROSS LINKING; CULTURE MEDIUM; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEWY BODY; NEUROBLASTOMA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INCLUSION BODIES; NEUROBLASTOMA; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; ROTENONE;

EID: 48249103154     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21644     Document Type: Article

References (77)

1. Auluck PK, Chan HYE, Trojanowski JQ, Lee VMY, Bonini NM. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-868.
2. Baker MG, Graham L. 2004. The journey: Parkinson's disease. Br Med J 329:611-614.
3. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
4. Betarbet R, Sherer TB, Greenamyre JT. 2002. Animal models of Parkinson's disease. Bioessays 24:308-318.
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
6. Bucana C, Saiki I, Nayar R. 1986. Uptake and accumulation of the vital dye hydroethidine in neoplastic cells. J Histochem Cytochem 34:1109-1115.
7. Burke RE. 1999. Alpha-synuclein and Parkinson's disease. Brain Res Bull 50:465-466.
8. Clayton DF, George JM. 1998. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21:249-254.
9. Clayton DF, George JM. 1999. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58:120-129.
10. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I. 2005. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816-830.
11. de Arriba SG, Stuchbury G, Yarin J, Burnell J, Loske C, Munch G. 2007. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells - protection by carbonyl scavengers. Neurobiol Aging 28:1044-1050.
12. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
13. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D, Wallace A. 1998. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440:71-75.
14. Feany MB, Bender WW. 2000. A Drosophila model of Parkinson's disease. Nature 404:394-398.
15. Forloni G, Bertani I, Calella AM, Thaler F, Invernizzi R. 2000. Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 47:632-640.
16. Forno LS. 1996. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272.
17. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH. 2000. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol 166:324-333.
18. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. 1999. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274:7619-7622.
19. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
20. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. 2001. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276:2380-2386.
21. Gomez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT. 2000. Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol 99:352-357.
22. Gow A, Duran D, Thom SR, Ischiropoulos H. 1996. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration. Arch Biochem Biophys 333:42-48.
23. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. 2007. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30:842-847.
24. Huang J, Liu H, Gu W, Yan Z, Xu Z, Yang Y, Zhu X, Li Y. 2006. A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease. Biomaterials 27:937-946.
25. Ischiropoulos H. 1998. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 356:1-11.
26. Iwata A, Maruyama M, Kanazawa I, Nukina N. 2001. Alpha-synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem 276:45320-45329.
27. Jenner P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13 Suppl 1:24-34.
28. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
29. Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P. 2003. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 106:83-88.
30. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108.
31. Kuhla B, Loske C, Garcia De Arriba S, Schinzel R, Huber J, Munch G. 2004. Differential effects of "advanced glycation endproducts" and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 111:427-439.
32. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL. 2002. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99:8968-8973.
33. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Munch G. 2000. Transition metal-mediated glycoxidation accelerates cross-linking of β-amyloid peptide. Eur J Biochem 267:4171-4178.
34. Lucking CB, Brice A. 2000. Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci 57:1894-1908.
35. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD. 2001. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171:29-45.
36. Lue LF, Yan SD, Stern DM, Walker DG. 2005. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 4:249-266.
37. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269.
38. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. 2002. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 277:19213-19219.
39. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, Schmidt AM. 1996. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088-1094.
40. Munch G, Cunningham AM, Riederer P, Braak E. 1998a. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease. Brain Res 796:307-310.
41. Munch G, Gerlach M, Sian J, Wong A, Riederer P. 1998b. Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol 44(Suppl 1):S85-S88.
42. Munch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P. 1998c. Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439-461.
43. Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P. 2000. Crosslinking of alpha-synuclein by advanced glycation end-products - an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20:253-257.
44. Nemes Z, Devreese B, Steinert PM, Van Beeumen J, Fesus L. 2004. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J 18:1135-1137.
45. Norris EH, Giasson BI, Ischiropoulos H, Lee VM. 2003. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278:27230-27240.
46. Olteanu A, Pielak GJ. 2004. Peroxidative aggregation of α-synuclein requires tyrosines. Protein Sci 13:2852-2856.
47. Perrin RJ, Woods WS, Clayton DF, George JM. 2001. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem 276:41958-41962.
48. Perticarari S, Presani G, Banfi E. 1994. A new flow cytometric assay for the evaluation of phagocytosis and the oxidative burst in whole blood. J Immunol Methods 170:117-124.
49. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
50. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL. 2007. Effect of 4-hydroxy-2-nonenal modification on α-synuclein aggregation. J Biol Chem 282:5862-5870.
51. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. 2005. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15:16R-28R.
52. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z. 1998. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153:1149-1155.
53. Schmidt AM, Yan SD, Yan SF, Stern DM. 2000. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498:99-111.
54. Shaikh S, Nicholson LF. 2006. Optimization of the Tet-On system for inducible expression of RAGE. J Biomol Techniq 17:283-292.
55. Sherer TB, Betarbet R, Greenamyre JT. 2002a. Environment, mitochondria, and Parkinson's disease. Neuroscientist 8:192-197.
56. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. 2002b. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22:7006-7015.
57. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. 2003. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341:87-90.
58. Shimoni Y, Hunt D, Chen K, Emmett T, Kargacin G. 2006. Differential autocrine modulation of atrial and ventricular potassium currents and of oxidative stress in diabetic rats. Am J Physiol Heart Circ Physiol 290:H1879-H1888.
59. Smith TA, Prayson RA. 1996. Lewy body disease. South Med J 89:1174-1180.
60. Smith WW, Jiang H, Pei Z, Tanaka Y, Morita H, Sawa A, Dawson VL, Dawson TM, Ross CA. 2005. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 14:3801-3811.
61. Souza JM, Giasson BI, Chen Q, Lee VMY, Ischiropoulos H. 2000. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275:18344-18349.
62. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
63. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95:6469-6473.
64. Takahashi T, Yamashita H, Nakamura T, Nagano Y, Nakamura S. 2002. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res 938:73-80.
65. Tanner CM OR, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. 1999. Parkinson disease in twins: an etiologic study. JAMA 281:341-346.
66. Teismann P, Schulz JB. 2004. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318:149-161.
67. Terry RD. 2000. Do neuronal inclusions kill the cell? J Neural Transm Suppl 59:91-93.
68. Testa CM, Sherer TB, Greenamyre JT. 2005. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134:109-118.
69. Trimmer PA, Borland MK, Keeney PM, Bennett JP Jr, Parker WD Jr. 2004. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 88:800-812.
70. Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E. 1998. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density hpoproteins. J Biol Chem 273:16058-16066.
71. Uversky VN, Fink AL. 2002. Amino acid determinants of α-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett 522:9-13.
72. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H. 1997. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett 239:45-48.
73. Watabe M, Nakaki T. 2004. Rotenone induces apoptosis via activation of bad in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther 311:948-953.
74. Wautier JL, Guillausseau PJ. 2001. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27:535-542.
75. Wersinger C, Sidhu A. 2002. Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy 1:221-242.
76. Yan SF, Ramasamy R, Naka Y, Schmidt AM. 2003. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159-1169.
77. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173.